Climb Bio’s (CLYM) “Buy” Rating Reaffirmed at BTIG Research

BTIG Research restated their buy rating on shares of Climb Bio (NASDAQ:CLYM) in a research note issued to investors on Monday morning,Benzinga reports. They currently have a $7.00 target price on the stock.

Several other research analysts also recently commented on CLYM. Oppenheimer assumed coverage on Climb Bio in a research note on Friday, June 6th. They set an “outperform” rating and a $10.00 target price for the company. Baird R W upgraded Climb Bio to a “strong-buy” rating in a report on Friday, August 15th. Robert W. Baird began coverage on Climb Bio in a report on Friday, August 15th. They set an “outperform” rating and a $9.00 price target on the stock. Finally, Wall Street Zen upgraded Climb Bio from a “sell” rating to a “hold” rating in a report on Saturday. Two research analysts have rated the stock with a Strong Buy rating and four have issued a Buy rating to the stock. Based on data from MarketBeat, Climb Bio currently has a consensus rating of “Buy” and a consensus price target of $9.00.

Climb Bio Trading Up 0.4%

Shares of NASDAQ CLYM opened at $2.32 on Monday. The company has a market cap of $157.20 million, a price-to-earnings ratio of -3.31 and a beta of -0.05. Climb Bio has a 12 month low of $1.05 and a 12 month high of $8.58. The stock has a 50-day moving average price of $1.93 and a two-hundred day moving average price of $1.50.

Climb Bio (NASDAQ:CLYM) last issued its earnings results on Tuesday, August 12th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.06. On average, sell-side analysts predict that Climb Bio will post -1.57 earnings per share for the current year.

Hedge Funds Weigh In On Climb Bio

A number of institutional investors have recently modified their holdings of the company. AQR Capital Management LLC acquired a new position in shares of Climb Bio during the first quarter worth approximately $27,000. XTX Topco Ltd acquired a new position in shares of Climb Bio during the first quarter worth approximately $34,000. Diadema Partners LP raised its position in shares of Climb Bio by 4.8% during the second quarter. Diadema Partners LP now owns 702,135 shares of the company’s stock worth $871,000 after purchasing an additional 32,332 shares during the period. Qube Research & Technologies Ltd acquired a new position in shares of Climb Bio during the second quarter worth approximately $43,000. Finally, Marshall Wace LLP acquired a new position in shares of Climb Bio during the second quarter worth approximately $46,000. 69.76% of the stock is owned by institutional investors and hedge funds.

About Climb Bio

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.